Von Hippel-Lindau Disease Clinical Trial
Official title:
68Ga-NY104 PET/CT and Conventional Imaging in Patients With Von Hippel-Lindau Disease: a Prospective, Single-center, Single-arm, Comparative Imaging Study
This is a prospective, single-center, single-arm, diagnostic phase 2 study in patients with von Hippel-Lindau disease. VHL disease is a rare syndrome characterized by VHL gene mutation and HIF activation. Although genetic testing is available, the manifestations of the syndrome are protean; therefore, imaging plays a crucial role in the identification of abnormalities and subsequent follow-up of lesions. For now, conventional imaging serves as the main radiologic modality in the characterization of VHL disease. In this study, we aim to evaluate the sensitivity of 68Ga-NY104 PET/CT in patients with VHL disease. 68Ga-NY104 is a novel small molecule PET tracer targeting carbonic anhydrase IX, which is a down-streaming target of HIF and overexpressed in HIF activation. 68Ga-NY104 PET/CT is likely to function as a sensitive imaging tool to identify VHL-related tumors and to impact patient management if additional lesions are identified. The hypotheses of this study are that - 68Ga-NY104 PET/CT can be used as an effective imaging modality in VHL syndrome with high sensitivity - 68Ga-NY104 PET/CT may detect lesions that are missed on conventional imaging and can result in management impact. A total of 19 patients will be recruited at Peking Union Medical College Hospital. As an exploratory end-point, a 68Ga-NODAGA-LM3 PET/CT sub-study will be performed in patients with evidence of neuroendocrine tumors.
Hypothesis The hypotheses of this study are that - 68Ga-NY104 PET/CT can be used as an effective imaging modality in VHL syndrome with high sensitivity - 68Ga-NY104 PET/CT may detect lesions that are missed on conventional imaging and can result in management impact. Objectives Primary objective 1. To determine the sensitivity of 68Ga-NY104 PET/CT using conventional imaging as reference. Secondary objectives 1. To determine the incremental management impact of 68Ga-NY104 PET/CT 2. To assess the interobserver agreement of 68Ga-NY104 PET/CT by comparing the two blinded independent readings Exploratory objective 1. To compare the per-patient, per-region, and per-lesion sensitivity of 68Ga-NY104 PET/CT to 68Ga-NODAGA-LM3 PET/CT in an exploratory endpoint Endpoints Primary endpoint 1. Per-patient, per-region, and per-lesion positive rate of 68Ga-NY104 using conventional imaging as ground truth. Secondary endpoints 1. Incremental impact of 68Ga-NY104 PET/CT on choice of management, defined as a decision to alter the original plan of treatment (based on conventional imaging) after considering the result of 68Ga-NY104 PET/CT (Impact is categorized as high, medium, low or no incremental impact.) 2. Observer agreement in interpretation of 68Ga-NY104 PET/CT between the two independent nuclear medicine readers. Exploratory endpoints 1. Per-patient, per-region, and per-lesion positive rate of 68Ga-NODAGA-LM3 using conventional imaging as ground truth. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00970970 -
Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
|
||
Completed |
NCT01168440 -
Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease
|
Phase 2 | |
Recruiting |
NCT06194669 -
Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule Cells
|
||
Recruiting |
NCT04074135 -
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Enrolling by invitation |
NCT03979833 -
Drivers of Hypoxia-induced Angiogenesis in Tumor Development
|
||
Active, not recruiting |
NCT04458935 -
Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma
|
||
Recruiting |
NCT05737602 -
Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease
|
N/A | |
Recruiting |
NCT03749980 -
MyVHL: Patient Natural History Study
|
||
Recruiting |
NCT05424016 -
Propranolol and Von Hippel-Lindau Disease
|
N/A | |
Recruiting |
NCT02420067 -
Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients
|
N/A | |
Completed |
NCT00052013 -
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
|
Phase 2 | |
Recruiting |
NCT04924075 -
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
|
Phase 2 | |
Recruiting |
NCT03050268 -
Familial Investigations of Childhood Cancer Predisposition
|
||
Completed |
NCT02108002 -
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
|
Phase 1 | |
Not yet recruiting |
NCT05843305 -
A Study of BPI-452080 in Subjects With Solid Tumors
|
Phase 1 | |
Completed |
NCT03108066 -
PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT00062166 -
Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease
|